2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: FHU Imminent

Poster-Disease-modifying Therapy

October 25, 2021

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study

Background: Patients with relapsing-remitting multiple sclerosis (RRMS) often experience disease activity despite receiving a...

Read More →

Platform-Disease Modifying Therapies

October 25, 2021

Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study

Background: The Work Productivity and Activity Impairment (WPAI) questionnaire is a patient-reported outcome that assesses percentage of...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC